Misplaced Pages

This is an old revision of this page, as edited by Wiiformii (talk | contribs) at 22:10, 19 December 2024 (→top: Typo fixing, typo(s) fixed: 1980’s → 1980s). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

Mcn 5707

Clinical data
Other names	McN-5707
Identifiers
IUPAC name (6R,10bR)-6-(2-chlorophenyl)-1,2,3,5,6,10b-hexahydropyrroloisoquinoline
CAS Number	96795-88-9
PubChem CID	126059
ChemSpider	112085
CompTox Dashboard (EPA)	DTXSID20914317
Chemical and physical data
Formula	C18H18ClN
Molar mass	283.80 g·mol
3D model (JSmol)	Interactive image
SMILES C1C2C3=CC=CC=C3(CN2C1)C4=CC=CC=C4Cl
InChI InChI=1S/C18H18ClN/c19-17-9-4-3-7-14(17)16-12-20-11-5-10-18(20)15-8-2-1-6-13(15)16/h1-4,6-9,16,18H,5,10-12H2/t16-,18-/m1/s1 Key:KWMNBUDYCCTHHL-SJLPKXTDSA-N

Mcn 5707 is a SNDRI agent designated for the treatment of depression. It was developed by Bruce Maryanoff of McNeil (now Johnson & Johnson) in the 1980s.

For related agents, see JNJ-7925476, McN 4612-z, McN-5292, McN-5558 & McN5652.

References

1. Maryanoff BE, Shank RP, Gardocki JF (1986). "McN-5707 and McN-5652-Z". Drugs of the Future. 11 (1): 18. doi:10.1358/dof.1986.011.01.51629.
2. Maryanoff BE, McComsey DF, Castanzo MJ, Setler PE, Gardocki JF, Shank RP, et al. (August 1984). "Pyrroloisoquinoline antidepressants. Potent, enantioselective inhibition of tetrabenazine-induced ptosis and neuronal uptake of norepinephrine, dopamine, and serotonin". Journal of Medicinal Chemistry. 27 (8): 943–6. doi:10.1021/jm00374a001. PMID 6747993.

• Serotonin–norepinephrine–dopamine reuptake inhibitors
• Stimulants
• Pyrroloisoquinolines
• Drugs developed by Johnson & Johnson
• Abandoned drugs